Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07185971 · ClinicalTrials.gov registry record · NA
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
A NA study of Homonymous Quadrantanopia and Homonymous Hemianopsia, sponsored by NeuroAEye.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07185971: Recruiting NA study of Homonymous Quadrantanopia and Homonymous Hemianopsia, sponsored by NeuroAEye.
NCT07185971 is a NA study of Homonymous Quadrantanopia and Homonymous Hemianopsia that is actively recruiting participants, run by NeuroAEye. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07185971, a NA study of Homonymous Quadrantanopia and Homonymous Hemianopsia, is actively recruiting participants, sponsored by NeuroAEye.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery. The PAVE regimen involves the use of a virtual reality headset to deliver visual stimulation to subjects diagnosed with visual field loss. The primary objective is to demonstrate that the clinical outcomes from exposure to the PAVE therapy (test group) are statistically superior to those achieved with a placebo (control group). The primary outcome is an increase in visual field area as measured with Goldmann-type kinetic perimetry. The secondary outcome will be demonstration that the subjective assessment of visual function using the National Eye Institute Visual Function Questionnaire (NEI-VFQ) is better for the test group when compared with the control group. The participants will visit the investigators office once per week for a minimum of eight weeks and a maximum of twenty four weeks and receive a therapy session. Every four weeks the participants visual field will be measured using kinetic perimetry. Every eight weeks the participant will complete the NEI-VFQ. Four weeks after the completion of the therapy sessions a follow up visit will take place where visual field measurement using kinetic perimetry and NEI-VFQ will be administered.
Primary Outcome
The visual field area is derived from the isopter plot output of semiautomated kinetic perimetry. A baseline visual field area will be taken and subsequent measurements will be compared to the baseline.
Conditions Studied
Interventions
- DEVICE PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display
- DEVICE PAVE Placebo
Study Locations (1)
Iowa
- Dr. D. M. Fitzgerald & Associates - Cedar Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT07185971 shows while recruiting
NCT07185971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Homonymous Quadrantanopia appearing as the primary indexed condition, and to 2 interventions - of which PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display is the first listed.
NCT07185971 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT07185971 about?
NCT07185971 is a clinical study titled "PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery". This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery. The PAVE regimen involves the use of a virtual reality headset to deliver visual st...
What is the current status of trial NCT07185971?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-09-22. Estimated completion is 2026-08.
What conditions does trial NCT07185971 study?
This clinical trial studies the following conditions: Homonymous Quadrantanopia, Homonymous Hemianopsia.
What interventions are being tested in trial NCT07185971?
The interventions under investigation include: PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display (DEVICE), PAVE Placebo (DEVICE).
Who is sponsoring clinical trial NCT07185971?
This trial is sponsored by NeuroAEye, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07185971 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homonymous Quadrantanopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07185971's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI